Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
<p><strong>Background:</strong> Glioblastoma is the most common and aggressive primary brain tumor with extremely poor prognosis, highlighting an urgent need for developing novel treatment options. Identifying epigenetic vulnerabilities of cancer cells can provide excellen...
Autors principals: | Ozyerli-Goknar, E, Kala, EY, Aksu, AC, Bulut, I, Cingöz, A, Nizamuddin, S, Biniossek, M, Seker-Polat, F, Morova, T, Aztekin, C, Kung, SHY, Syed, H, Tuncbag, N, Gönen, M, Philpott, M, Cribbs, AP, Acilan, C, Lack, NA, Onder, TT, Timmers, HTM, Bagci-Onder, T |
---|---|
Format: | Journal article |
Idioma: | English |
Publicat: |
BioMed Central
2023
|
Ítems similars
-
Epigenetic-focused CRISPR/Cas9 screen identifies (absent, small, or homeotic)2-like protein (ASH2L) as a regulator of glioblastoma cell survival
per: Ezgi Ozyerli-Goknar, et al.
Publicat: (2023-11-01) -
EPIKOL, a chromatin-focused CRISPR/Cas9-based screening platform, to identify cancer-specific epigenetic vulnerabilities
per: Yedier-Bayram, O, et al.
Publicat: (2022) -
The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma
per: Ozyerli-Goknar, E, et al.
Publicat: (2019) -
Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer
per: Saraç, H, et al.
Publicat: (2019) -
Homeotic shift at the dawn of the turtle evolution
per: Tomasz Szczygielski
Publicat: (2017-01-01)